These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 11734111)
81. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Sousa SF; Fernandes PA; Ramos MJ Curr Med Chem; 2008; 15(15):1478-92. PubMed ID: 18537624 [TBL] [Abstract][Full Text] [Related]
82. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275 [TBL] [Abstract][Full Text] [Related]
83. Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Crul M; de Klerk GJ; Beijnen JH; Schellens JH Anticancer Drugs; 2001 Mar; 12(3):163-84. PubMed ID: 11290863 [TBL] [Abstract][Full Text] [Related]
84. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Jabbour E; Kantarjian H; Cortes J Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806 [TBL] [Abstract][Full Text] [Related]
85. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Gibbs JB; Oliff A Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250 [TBL] [Abstract][Full Text] [Related]
86. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Feldkamp MM; Lau N; Roncari L; Guha A Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071 [TBL] [Abstract][Full Text] [Related]
96. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. Rowinsky EK; Windle JJ; Von Hoff DD J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163 [TBL] [Abstract][Full Text] [Related]
97. Farnesyltransferase inhibitors. Adjei AA Cancer Chemother Biol Response Modif; 2005; 22():123-33. PubMed ID: 16110610 [No Abstract] [Full Text] [Related]
98. Ras inhibitors and radiation therapy. Jones HA; Hahn SM; Bernhard E; McKenna WG Semin Radiat Oncol; 2001 Oct; 11(4):328-37. PubMed ID: 11677657 [TBL] [Abstract][Full Text] [Related]
99. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Mahgoub N; Taylor BR; Gratiot M; Kohl NE; Gibbs JB; Jacks T; Shannon KM Blood; 1999 Oct; 94(7):2469-76. PubMed ID: 10498620 [TBL] [Abstract][Full Text] [Related]
100. Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias. Lancet JE; Rosenblatt JD; Karp JE Semin Hematol; 2002 Jul; 39(3 Suppl 2):31-5. PubMed ID: 12214291 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]